These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
706 related items for PubMed ID: 19602134
1. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC. Liver Int; 2009 Nov; 29(10):1485-93. PubMed ID: 19602134 [Abstract] [Full Text] [Related]
2. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Su WW, Lin CL, Yang HC, Chen PJ, Chen DS, Liu CJ, Taiwan Liver-Net Consortium. Hepatology; 2013 Jun; 57(6):2135-42. PubMed ID: 23322699 [Abstract] [Full Text] [Related]
4. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection. Yeh ML, Hsieh MY, Huang CI, Huang CF, Hsieh MH, Huang JF, Dai CY, Chuang WL, Yu ML. J Gastroenterol Hepatol; 2016 Apr; 31(4):835-41. PubMed ID: 26478984 [Abstract] [Full Text] [Related]
5. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. Ramos B, Núñez M, Rendón A, Berdún MA, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Barreiro P, Romero M, Labarga P, Guardiola JM, Garcia-Samaniego J, Soriano V. J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758 [Abstract] [Full Text] [Related]
11. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. Castells L, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, Rodriguez M, Bernal C, Suarez F, Antela A, Olivares S, Del Campo S, Laguno M, Fernandez JR, de la Rosa G, Agüero F, Perez I, González-García J, Esteban-Mur JI, Miro JM, FIPSE LT-HIV Investigators. J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748 [Abstract] [Full Text] [Related]
12. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T. Clin Drug Investig; 2008 Jan; 28(1):9-16. PubMed ID: 18081356 [Abstract] [Full Text] [Related]
18. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P, Austrian Hepatitis Study Group. Gastroenterology; 2008 Aug; 135(2):451-8. PubMed ID: 18503773 [Abstract] [Full Text] [Related]
19. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response. El Khayat HR, Fouad YM, El Amin H, Rizk A. Trop Gastroenterol; 2012 Aug; 33(2):112-7. PubMed ID: 23025057 [Abstract] [Full Text] [Related]
20. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection. Peribañez-Gonzalez M, da Silva MH, Vilar FC, Seixas-Santos Nastri AC, Ferreira PA, Focaccia R, Mendes Correa MC. Ann Hepatol; 2013 Aug; 12(2):228-35. PubMed ID: 23396734 [Abstract] [Full Text] [Related] Page: [Next] [New Search]